Amyris, Inc. (NASDAQ:AMRS) Given Consensus Rating of “Hold” by Brokerages

Shares of Amyris, Inc. (NASDAQ:AMRS – Get Rating) have been given a consensus recommendation of “Hold” by the eleven analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $3.06.

Several brokerages have issued reports on AMRS. HC Wainwright dropped their price target on Amyris from $22.00 to $5.00 in a research note on Thursday, March 16th. Piper Sandler dropped their price target on Amyris from $1.50 to $1.00 in a research note on Wednesday, April 26th. StockNews.com began coverage on Amyris in a report on Friday, March 17th. They set a “sell” rating for the company. Canaccord Genuity Group began coverage on Amyris in a report on Friday, April 28th. They set a “buy” rating and a $1.50 price objective for the company. Finally, Jefferies Financial Group downgraded Amyris from a “buy” rating to a “hold” rating and decreased their price objective for the company from $3.10 to $0.65 in a report on Thursday, May 18th.

Insider Buying and Selling

In related news, COO Eduardo Alvarez sold 231,368 shares of the company’s stock in a transaction on Wednesday, April 5th. The stock was sold at an average price of $1.23, for a total transaction of $284,582.64. Following the completion of the sale, the chief operating officer now owns 612,546 shares in the company, valued at $753,431.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 36.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amyris

Institutional investors have recently bought and sold shares of the stock. Williams Jones Wealth Management LLC. bought a new stake in Amyris during the first quarter worth $45,000. FCA Corp TX purchased a new position in Amyris in the first quarter worth $48,000. Arete Wealth Advisors LLC purchased a new position in Amyris in the first quarter worth $15,811,000,000. Metropolitan Life Insurance Co NY boosted its position in Amyris by 109.5% in the third quarter. Metropolitan Life Insurance Co NY now owns 11,936 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 6,238 shares during the last quarter. Finally, Atom Investors LP purchased a new position in Amyris in the third quarter worth $37,000. Institutional investors own 43.08% of the company’s stock.

Amyris Price Performance

Amyris stock opened at $0.71 on Tuesday. The stock’s 50 day moving average is $1.01 and its 200 day moving average is $1.44. The firm has a market cap of $260.60 million, a P/E ratio of -0.37 and a beta of 1.15. Amyris has a one year low of $0.55 and a one year high of $4.86.

Amyris (NASDAQ:AMRS – Get Rating) last issued its quarterly earnings results on Wednesday, March 15th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.33). The business had revenue of $75.80 million during the quarter, compared to analysts’ expectations of $104.10 million. Equities analysts anticipate that Amyris will post -0.57 earnings per share for the current fiscal year.

Amyris Company Profile

(Get Rating)

Amyris, Inc engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.